• 1
    Office of Research and Development, U.S. Environmental Protection Agency. 2008. Pharmaceuticals and personal care products (PPCPs): Relevant literature. Las Vegas, NV.
  • 2
    Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT. 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: A national reconnaissance. Environ Sci Technol 36: 12021211.
  • 3
    Daughton CG. 2007. Pharmaceuticals in the environment: Sources and their management. In PetrovicM, BarceloD, eds, Analysis, Fate and Removal of Pharmaceuticals in the Water Cycle, Vol 50. Wilson & Wilson's Comprehensive Analytical Chemistry Series. Elsevier Science, Amsterdam, The Netherlands, pp 158.
  • 4
    Winker M, Faika D, Gulyas H, Otterpohl R. 2008. A comparison of human pharmaceutical concentrations in raw municipal wastewater and yellowwater. Sci Total Environ 399: 96104.
  • 5
    Boxall ABA. 2002. The environmental side effects of medication: How are human and veterinary medicines in soils and water bodies affecting human and environmental health?. EMBO Rep 5: 11101116.
  • 6
    Boxall ABA, Fogg LA, Blackwell PA, Kay P, Pemberton EJ, Croxford A. 2004. Veterinary medicines in the environment. Rev Environ Contam Toxicol 180: 191.
  • 7
    Cunningham VL, Buzby M, Hutchinson T, Mastrocco F, Parke N, Roden N. 2006. Effects of human pharmaceuticals on aquatic life: Next steps. Environ Sci Technol 40: 34563462.
  • 8
    Ruhoy I, Daughton C. 2008. Beyond the medicine cabinet: An analysis of where and why medications accumulate. Environ Int 34: 11571169.
  • 9
    Daughton CG. 2003. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ Health Perspect 111: 757774.
  • 10
    Daughton CG. 2003. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. II. Drug disposal, waste reduction, and future directions. Environ Health Perspect 111: 775785.
  • 11
    Glassmeyer S, Hinchey E, Boehme S, Daughton C, Ruhoy I, Conerly O, Daniels R, Lauer L, McCarthy M, Nettesheim T, Sykes K, Thompson V. 2009. Disposal practices for unwanted residential medications in the United States. Environ Int 35: 566572.
  • 12
    Bound JP, Kitsou K, Voulvoulis N. 2006. Household disposal of pharmaceuticals and perception of risk to the environment. Environ Toxicol Pharmacol 21: 301307.
  • 13
    Doerr-MacEwen NA, Haight ME. 2006. Expert stakeholders' views on the management of human pharmaceuticals in the environment. Environ Manag 38: 853866.
  • 14
    Seehusen DA, Edwards J. 2006. Patient practices and beliefs concerning disposal of medications. J Am Board Fam Med 19: 542547.
  • 15
    Ruhoy IS, Daughton CG. 2007. Types and quantities of leftover drugs entering the environment via disposal to sewage—Revealed by coroner records. Sci Total Environ 388: 137148.
  • 16
    Daughton CG, Ruhoy IS. 2008. The afterlife of drugs and the role of PharmEcovigilance. Drug Saf 31: 10691082.
  • 17
    Fasola G, Aita M, Marini L, Follador A, Tosolini M, Mattioni L, Mansutti M, Piga A, Brusaferro S, Aprile G. 2008. Drug waste minimisation and cost-containment in medical oncology: Two-year results of a feasibility study. BMC Health Serv Res 8:70.
  • 18
    National Cancer Institute. 2008. Dictionary of cancer terms: Pharmacokinetics. National Institutes of Health, Washington, DC, USA.
  • 19
    Castegnaro M, Hansel S. 2006. Antineoplastic drugs in sewage from hospitals and households. Environment, Risques & Santé 5: 266270.
  • 20
    Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. 2007. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 8: 171183.
  • 21
    Burt A, Annest J, Ballesteros M, Budnitz D. 2006. Nonfatal, unintentional medication exposures among young children—United States, 2001–2003. JAMA (J Am Med Assoc) 295: 882884.
  • 22
    Wysowski DK. 2007. Surveillance of prescription drug-related mortality using death certificate data. Drug Saf 30: 533540.
  • 23
    Office of National Drug Control Policy. 2007. Proper disposal of prescription drugs. Washington, DC, USA.
  • 24
    Drug Enforcement Administration. 2008. Disposal of controlled substances by persons not registered with the Drug Enforcement Administration. 21 CFR Parts 1300, 1301, 1304, 1305, and 1307. Fed Reg 74: 34803487.
  • 25
    Kostich MS, Lazorchak JM. 2008. Risks to aquatic organisms posed by human pharmaceutical use. Sci Total Environ 389: 329339.
  • 26
    Cooper ER, Siewicki TC, Phillips K. 2008. Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment. Sci Total Environ 398: 2633.
  • 27
    Anderson PD, D'Aco VJ, Shanahan P, Chapra SC, Buzby ME, Cunningham VL, DuPlessie BM, Hayes EP, Mastrocco FJ, Parke NJ, Rader JC, Samuelian JH, Schwab BW. 2004. Screening analysis of human pharmaceutical compounds in U.S. surface waters. Environ Sci Technol 38: 838849.
  • 28
    Wilkosz MF, Bogner RH. 2003. Transdermal drug delivery—Part 1: Current status. US Pharm 28: 4055.
  • 29
    Fisher PMJ, Scott R. 2008. Evaluating and controlling pharmaceutical emissions from dairy farms: A critical first step in developing a preventative management approach. Journal of Cleaner Production 16: 14371446.
  • 30
    Thaysen JH, Schwartz IL. 1953. The permeability of human sweat glands to a series of sulfonamide compounds. J Exp Med 98: 261268.
  • 31
    Rouen D, Dolan K, Kimber J. 2001. A review of drug detection testing and an examination of urine, hair, saliva and sweat. Technical Report 120. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
  • 32
    Fortner NA. 2008. The detection of drugs in sweat. In JenkinsAJ, ed, Forensic Science and Medicine: Drug Testing in Alternate Biological Specimens. Humana, Totowa, NJ, USA, pp 101116.
  • 33
    Parnas J, Flachs H, Gram L, Würtz-Jørgensen A. 1978. Excretion of antiepileptic drugs in sweat. Acta Neurol Scand 58: 197204.
  • 34
    Leggett R, Lee-Smith EE, Jickells SM, Russell DA. 2007. “Intelligent” fingerprinting: Simultaneous identification of drug metabolites and individuals by using antibody-functionalized nanoparticles. Angew Chem Int Ed 46: 41004103.
  • 35
    Pichini S, Navarro M, Pacifici R, Zuccaro P, Ortuno J, Farre M, Roset PN, Segura J, de la Torre R. 2003. Usefulness of sweat testing for the detection of MDMA after a single-dose administration. J Anal Toxicol 27: 294303.
  • 36
    Tobin DJ. 2006. Biochemistry of human skin-our brain on the outside. Chem Soc Rev 35: 5267.
  • 37
    Preston KL, Huestis MA, Wong CJ, Umbricht A, Goldberger BA, Cone EJ. 1999. Monitoring cocaine use in substance-abuse-treatment patients by sweat and urine testing. J Anal Toxicol 23: 313322.
  • 38
    Joss A, Zabczynski S, Gobel A, Hoffmann B, Loffler D, McArdell CS, Ternes TA, Thomsen A, Siegrist H. 2006. Biological degradation of pharmaceuticals in municipal wastewater treatment: Proposing a classification scheme. Water Res 40: 16861696.
  • 39
    Appenzeller BMR, Schummer C, Rodrigues SB, Wennig R. 2007. Determination of the volume of sweat accumulated in a sweat-patch using sodium and potassium as internal reference. J Chromatogr B 852: 333337.
  • 40
    Høiby N, Jarløv JO, Kemp M, Tvede M, Bangsborg JM, Kjerulf A, Pers C, Hansen H. 1997. Excretion of ciprofloxacin in sweat and multiresistantStaphylococcus epidermidis. Lancet 349: 167169.
  • 41
    Schneider S, Ait-m-bark Z, Schummer C, Lemmer P, Yegles M, Appenzeller B, Wennig R. 2008. Case report: Determination of fentanyl in sweat and hair of a patient using transdermal patches. J Anal Toxicol 32: 260264.
  • 42
    Daughton CG. 2008. Pharmaceuticals as environmental pollutants: The ramifications for human exposure. In HeggenhougenK, QuahS, eds, International Encyclopedia of Public Health, Vol 5. Academic, Oxford, UK, pp 66102.
  • 43
    Martin ANF, George R, Jones AD, Frank M. 2007. The nondestructive identification of solid over-the-counter medications using single particle aerosol mass spectrometry. Rapid Commun Mass Spectrom 21: 35613568.
  • 44
    Takats Z, Wiseman JM, Gologan B, Cooks RG. 2004. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science 306: 471473.
  • 45
    Williams JP, Patel VJ, Holland R, Scrivens JH. 2006. The use of recently described ionisation techniques for the rapid analysis of some common drugs and samples of biological origin. Rapid Commun Mass Spectrom 20: 14471456.
  • 46
    Høiby N, Pers C, Johansen HK, Hansen H, The Copenhagen Study Group on Antibiotics in Sweat. 2000. Excretion of β-lactam antibiotics in sweat—A neglected mechanism for development of antibiotic resistance?. Antimicrob Agents Chemother 44: 28552857.
  • 47
    Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, Sterry W, Lademann J. 2005. Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrody-sesthesia syndrome?. Ann Oncol 16: 12101211.
  • 48
    Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. 2007. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 18: 11591164.
  • 49
    Madsen E, Larsen H. 1988. Excretion of mutagens in sweat from humans treated with anti-neoplastic drugs. Cancer Lett 40: 199202.
  • 50
    Mader R, Rizovski B, Steger G, Wachter A, Kotz R, Rainer H. 1996. Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Arch Environ Health 51: 310314.
  • 51
    Fransman W, Vermeulen R, Kromhout H. 2005. Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int Arch Occup Environ Health 78: 403412.
  • 52
    Meijster T, Fransman W, Veldhof R, Kromhout H. 2006. Exposure to antineoplastic drugs outside the hospital environment. Ann Occup Hyg 50: 657664.
  • 53
    Connor TH, Shults M, Fraser MP. 2000. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37°C using a desiccator technique. Mutat Res 470: 8592.
  • 54
    Kiffmeyer T, Kube C, Opiolka S, Schmidt K, Schöppe G, Sessink P. 2002. Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: Implications for occupational safety. Pharm J 268: 331337.
  • 55
    Fransman W, Huizer D, Tuerk J, Kromhout H. 2007. Inhalation and dermal exposure to eight antineoplastic drugs in an industrial laundry facility. Int Arch Occup Environ Health 80: 396403.
  • 56
    Fransman W. 2006. Antineoplastic drugs: Occupational exposure and health risks. PhD thesis. Utrecht University, Nijkerk, The Netherlands.
  • 57
    Monthly Prescribing Reference. 2008. Monthly Prescribing Reference Database: Dermatological disorders. Haymarket Media, New York, NY, USA.
  • 58
    Niazi SK. 2004. Handbook of Pharmaceutical Manufacturing Formulations: Semisolid Products, Vol 4. CRC, Boca Raton, FL, USA, pp 1263.
  • 59
    D'Ascenzo G, Di Corcia A, Gentili A, Mancini R, Mastropasqua R, Nazzari M, Samperi R. 2003. Fate of natural estrogen conjugates in municipal sewage transport and treatment facilities. Sci Total Environ 302: 199209.
  • 60
    Arcand-Hoy LD, Nimrod AC, Benson WH. 1998. Endocrine-modulating substances in the environment: Estrogenic effects of pharmaceutical products. Int J Toxicol 17: 139158.
  • 61
    Walters KA, Brain KR, Green DM, James VJ, Watkinson AC, Sands RH. 1998. Comparison of the transdermal delivery of estradiol from two gel formulations. Maturitas 29: 189195.
  • 62
    Al-Dujaili EAS. 2006. Development and validation of a simple and direct ELISA method for the determination of conjugated (glucuronide) and non-conjugated testosterone excretion in urine. Clin Chim Acta 364: 172179.
  • 63
    Timón Andrada R, Maynar Marino M, Muñoz Marín D, Olcina Camacho GJ, Caballero MJ, Maynar Mariño JI. 2007. Variations in urine excretion of steroid hormones after an acute session and after a 4-week programme of strength training. Eur J Appl Physiol 99: 6571.
  • 64
    Tanner T, Marks R. 2008. Delivering drugs by the transdermal route: Review and comment. Skin Res Technol 14: 249260.
  • 65
    Chang H, Hu J, Shao B. 2007. Occurrence of natural and synthetic glucocorticoids in sewage treatment plants and receiving river waters. Environ Sci Technol 41: 34623468.
  • 66
    Piram A, Salvador A, Gauvrit J-Y, Lanteri P, Faure R. 2008. Development and optimisation of a single extraction procedure for the LC/MS/MS analysis of two pharmaceutical classes residues in sewage treatment plant. Talanta 74: 14631475.
  • 67
    Siemens J, Huschek G, Siebe C, Kaupenjohann M. 2008. Concentrations and mobility of human pharmaceuticals in the world's largest wastewater irrigation system, Mexico City-Mezquital Valley. Water Res 42: 21242134.
  • 68
    OSPAR Commission. 2007. OSPAR List of Chemicals for Priority Action (Update 2007). Reference 2004–12. Convention for the Protection of the Marine Environment of the North-east Atlantic, OSPAR Commission on Hazardous Substances. London, UK.
  • 69
    Hilton MJ, Thomas KV, Ashton D. 2003. Targeted monitoring programme for pharmaceuticals in the aquatic environment. R&D Technical Report P6–012/06/TR. Environment Agency, Bristol, UK.
  • 70
    Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413420.
  • 71
    Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22: 1123.
  • 72
    Custodio JM, Wu CY, Benet LZ. 2008. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Delivery Rev 60: 717733.
  • 73
    Johnson R, Nusbaum BP, Horwitz SN, Frost P. 1983. Transfer of topically applied tetracycline in various vehicles. Arch Dermatol 119: 660663.
  • 74
    Kunz GJ, Klein KO, Clemons RD, Gottschalk ME, Jones KL. 2004. Virilization of young children after topical androgen use by their parents. Pediatrics 114: 282284.
  • 75
    Bhowmick SK, Ricke T, Rettig KR. 2007. Sexual precocity in a 16-month-old boy induced by indirect topical exposure to testosterone. Clin Pediatr (Phila) 46: 540543.
  • 76
    Franklin SL, Geffner ME. 2003. Precocious puberty secondary to topical testosterone exposure. J Pediatr Endocrinol Metab 16: 107110.
  • 77
    Yu YM, Punyasavatsu N, Elder D, D'Ercole AJ. 1999. Sexual development in a two-year-old boy induced by topical exposure to testosterone. Pediatrics 104:e23.
  • 78
    Rolf C, Knie U, Lemmnitz G, Nieschlag E. 2002. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol 56: 637641.
  • 79
    ZumBrunnen TL, Meuwsen I, de Michiel V, Brennan JJ. 2006. The effect of washing and the absence of interindividual transfer of estradiol gel: A direct skin-to-skin contact study in postmenopausal women. American Journal of Drug Delivery 4: 8995.
  • 80
    Brachet C, Vermeulen J, Heinrichs C. 2005. Children's virilization and the use of a testosterone gel by their fathers. Eur J Pediatr 164: 646647.
  • 81
    Wester RC, Hui X, Maibach HI. 2006. In vivo human transfer of topical bioactive drug between individuals: Estradiol. J Investig Dermatol 126: 21902193.
  • 82
    Montgomery J. 2004. Strange progesterone saga. MLO Med Lab Obs 36:8.
  • 83
    Wolthuis A, de Vreeze J. 2005. Unexpected testosterone result for external quality assessment scheme sample. Clin Chem 51: 475476.
  • 84
    Richman C, Castensson S. 2008. Impact of waste pharmaceuticals: An environmental hazard or “greenwash”?. Pharm J 280: 335342.
  • 85
    Marquardt KA, Tharratt RS, Musallam NA. 1995. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 29: 969971.
  • 86
    McCormick CG. 2006. Regulatory challenges for new formulations of controlled substances in today's environment. Drug Alcohol Depend 83: S63S67.
  • 87
    Evans JD, Evans EW. 2007. Review of eight restricted-access programs and potential implications for pharmacy. Am J Health Syst Pharm 64: 13021310.
  • 88
    Scheindlin S. 2004. Transdermal drug delivery: Past, present, future. Mol Interv 4: 308312.
  • 89
    Musson SE, Townsend TG. 2009. Pharmaceutical compound content of municipal solid waste. J Hazard Mater 162: 730735.
  • 90
    Geurts MGJ, de Boer W, de Graaf JS, van Ginkel CG. 2007. Environmental exposure assessment of ethinyl estradiol (EE) from a combined hormonal vaginal contraceptive ring after disposal; leaching from landfills. Sci Total Environ 377: 366370.
  • 91
    Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, Lazorchak JM, Flick RW. 2007. Collapse of a fish population after exposure to a synthetic estrogen. Proc Natl Acad Sci USA 104: 88978901.
  • 92
    Institute of Safe Medicine Practice. 2005. New fentanyl warnings: More needed to protect patients. Eur J Hosp Pharm Pract 11:68.
  • 93
    Woodall KL, Martin TL, McLellan BA. 2008. Oral abuse of fentanyl patches (Duragesic): Seven case reports. J Forensic Sci 53: 222225.
  • 94
    Teske J, Weller JP, Larsch K, Tröger HD, Karst M. 2007. Fatal outcome in a child after ingestion of a transdermal fentanyl patch. Int J Leg Med 121: 147151.
  • 95
    Horowitz R, Mazor SS, Aks SE, Leikin JB. 2005. Accidental clonidine patch ingestion in a child. Am J Ther 12: 272274.
  • 96
    Tharp AM, Winecker RE, Winston DC. 2004. Fatal intravenous fentanyl abuse: Four cases involving extraction of fentanyl from transdermal patches. Am J Forensic Med Pathol 25: 178181.
  • 97
    Martin TL, Woodall KL, McLellan BA. 2006. Fentanyl-related deaths in Ontario, Canada: Toxicological findings and circumstances of death in 112 cases (2002–2004). J Anal Toxicol 30: 603610.
  • 98
    Woolf A, Burkhart K, Caraccio T, Litovitz T. 1997. Childhood poisoning involving transdermal nicotine patches. Pediatrics 99:e4.
  • 99
    Flannagan LM, Butts JD, Anderson WH. 1996. Fentanyl patches left on dead bodies—Potential source of drug for abusers. J Forensic Sci 41: 320321.
  • 100
    Yerasi AB, Butts JD. 1997. Disposal of used fentanyl patches. Am J Health Syst Pharm 54: 8586.
  • 101
    Hamscher G, Pawelzick HT, Sczesny S, Nau H, Hartung J. 2003. Antibiotics in dust originating from a pig-fattening farm: A new source of health hazard for farmers?. Environ Health Perspect 111: 15901594.
  • 102
    U.S Fish and Wildlife Service. 2008. SMARxT Disposal: A prescription for a healthy planet. The American Pharmacists Association and the Pharmaceutical Research and Manufacturers of America. Arlington, VA, USA.
  • 103
    De Bolle L, Mehuys E, Adriaens E, Remon J-P, Van Bortel L, Christiaens T. 2008. Home medication cabinets and self-medication: A Source of potential health threats?. Ann Pharmacother 42: 572579.
  • 104
    Stubbs J, Haw C, Dickens G. 2008. Dose form modification—A common but potentially hazardous practice. A literature review and study of medication administration to older psychiatric inpatients. Int Psychogeriatr 20: 616627.
  • 105
    Cone EJ. 2006. Ephemeral profiles of prescription drug and formulation tampering: Evolving pseudoscience on the Internet. Drug Alcohol Depend 83: S31S39.
  • 106
    Mitchell JF. 2009. Oral dosage forms that should not be crushed. Institute for Safe Medication Practices, Horsham, PA, USA.
  • 107
    Pharmacist's Letter. 2007. Proper disposal of expired or unwanted drugs. Pharmacist's Letter 23:230401.
  • 108
    AB Innovations. 2008. Pill crushers. Sumas, WA, USA.
  • 109
    Gebhart F. 2008. Pharmacy edges toward medication returns. Drug Top 152(4):25.
  • 110
    Halford B. 2008. Formulations for fighting abuse: Opioid makers aim to thwart misuse with excipients, additives, and antagonists. Chem Eng News 86: 4041.
  • 111
    Prüss A, Giroult E, Rushbrook P. 1999. Safe Management of Wastes from Health-Care Activities: A Practical Guide. World Health Organization, Geneva, Switzerland.
  • 112
    Health Care Without Harm. August 2001. Non-incineration medical waste treatment technologies: A resource for hospital administrators, facility managers, health care professionals, environmental advocates, and community members. Arlington, VA, USA.
  • 113
    Shappell NW, Vrabel MA, Madsen PJ, Harrington G, Billey LO, Hakk H, Larsen GL, Beach ES, Horwitz CP, Ro K, Hunt PG, Collins TJ. 2008. Destruction of estrogens using Fe-TAML/peroxide catalysis. Environ Sci Technol 42: 12961300.
  • 114
    Hirose J, Kondo F, Nakano T, Kobayashi T, Hiro N, Ando Y, Takenaka H, Sano K. 2005. Inactivation of antineoplastics in clinical wastewater by electrolysis. Chemosphere 60: 10181024.
  • 115
    National Institute for Occupational Safety and Health. 2004. Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings, Appendix A: Drugs considered hazardous. Publication 2004–165. Atlanta, GA, USA.
  • 116
    Connor TH, McDiarmid MA. 2006. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 56: 354365.
  • 117
    American Society of Health-System Pharmacists. 2006. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm 63: 11721193.
  • 118
    Meyer S, Eddleston M, Bailey B, Desel H, Gottschling S, Gortner L. 2007. Unintentional household poisoning in children. Klin Padiatr 219: 254279.
  • 119
    Bar-Oz B, Levichek Z, Koren G. 2004. Medications that can be fatal for a toddler with one tablet or teaspoonful: A 2004 update. Paediatr Drugs 6: 123126.
  • 120
    Bradley TJ, Williams WH. 1975. Evaluation of medicines returned in Manchester DUMP campaign. Pharm J 215:542, 547.
  • 121
    Harris DW, Karandikar DS, Spencer MG, Leach RH, Bower AC, Mander GA. 1979. Returned-medicines campaign in Birmingham. Lancet 313: 599601.
  • 122
    Doerr-MacEwen NA. 2007. The management of human pharmaceuticals in the environment. PhD thesis. University of Waterloo, Waterloo, ON, Canada.
  • 123
    Jjemba PK. 2006. Excretion and ecotoxicity of pharmaceutical and personal care products in the environment. Ecotoxicol Environ Saf 63: 113130.
  • 124
    Braybrook S, John DN, Leong K. 1999. A survey of why medicines are returned to pharmacies. Pharm J 263:R30.
  • 125
    Ruhoy IS. 2008. Examining unused pharmaceuticals in the environment. PhD thesis. University of Nevada, Las Vegas, NV, USA.
  • 126
    Boothby LA, Doering PL, Hatton RC. 2003. Carisoprodol: A marginally effective skeletal muscle relaxant with serious abuse potential. Hosp Pharm 38: 337345.
  • 127
    Soliman MA, Pedersen JA, Park H, Castaneda-Jimenez A, Stenstrom MK, Suffet IH. 2007. Human pharmaceuticals, antioxidants, and plasticizers in wastewater treatment plant and water reclamation plant effluents. Water Environ Res 79: 156167.
  • 128
    Thomas Reid Associates. 2006. Santa Clara Valley Water District Stream Flow Augmentation Project: Upper Silver Creek and Coyote Creek Initial Study/Mitigated Negative Declaration. Santa Clara Valley Water District. San Jose, CA, USA.
  • 129
    Pedersen JA, Yeager MA, Suffet IH. 2002. Characterization and mass load estimates of organic compounds in agricultural irrigation runoff. Water Sci Technol 45: 103110.
  • 130
    Gebhart F. 2008. Agencies flush original strategies in favor of promoting drug take-back programs. Drug Top 152(9):25.
  • 131
    Lienert J, Burki T, Escher BI. 2007. Reducing micropollutants with source control: Substance flow analysis of 212 pharmaceuticals in faeces and urine. Water Sci Technol 56: 8796.
  • 132
    Johnson HL, Maibach HI. 1971. Drug excretion in human eccrine sweat. J Investig Dermatol 56: 182188.
  • 133
    Zlateva S, Marinov P, Sabeva Y. 2007. Determination of toxic substances in sweat secret of severe forms of poisoning - Toxic coma. Clinical meaning. Journal of IMAB Book 1: 8385.
  • 134
    Barnes AJ, Smith ML, Kacinko SL, Schwilke EW, Cone EJ, Moolchan ET, Huestis MA. 2008. Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. Clin Chem 54: 172180.
  • 135
    Huestis MA, Oyler JM, Cone EJ, Wstadik AT, Schoendorfer D, Joseph RE. 1999. Sweat testing for cocaine, codeine and metabolites by gas chromatography-mass spectrometry. J Chromatogr B 733: 247264.
  • 136
    Kidwell DA, Holland JC, Athanaselis S. 1998. Testing for drugs of abuse in saliva and sweat. J Chromatogr B 713: 111135.
  • 137
    Burns M, Baselt RC. 1995. Monitoring drug use with a sweat patch: An experiment with cocaine. J Anal Toxicol 19: 4148.
  • 138
    Schwilke EW, Barnes AJ, Kacinko SL, Cone EJ, Moolchan ET, Huestis MA. 2006. Opioid disposition in human sweat after controlled oral codeine administration. Clin Chem 52: 15391545.
  • 139
    Kintz P, Tracqui A, Jamey C, Mangin P. 1996. Detection of codeine and phenobarbital in sweat collected with a sweat patch. J Anal Toxicol 20: 197210.
  • 140
    Cirimele V, Kintz P, Gosselin O, Ludes B. 2000. Clozapine dose-concentration relationships in plasma, hair and sweat specimens of schizophrenic patients. Forensic Sci Int 107: 289300.
  • 141
    Kintz P, Tracqui A, Mangin P. 1996. Sweat testing for benzodiazepines. J Forensic Sci 41: 851854.
  • 142
    Faergemann J, Laufen H. 1993. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 18: 102106.
  • 143
    Shah VP, Epstein WL, Riegelman S. 1974. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Investig 53: 16731678.
  • 144
    Hoharitanon S, Chaichalotornkul J, Sindhupak W. 2005. A comparison of the efficacy between two itraconazole generic products and the innovative itraconazole in the treatment of tinea pedis. J Med Assoc Thail 88(Suppl. 4):S167S172.
  • 145
    Taylor JR, Watson ID, Tames FJ, Lowe D. 1998. Detection of drug use in a methadone maintenance clinic: Sweat patches versus urine testing. Addiction 93: 847853.
  • 146
    Fucci N, De Giovanni N, Scarlata S. 2008. Sweat testing in addicts under methadone treatment: An Italian experience. Forensic Sci Int 174: 107110.
  • 147
    Ishiyama I, Nagai T, Nagai T, Komuro E, Momose T, Akimori N. 1979. The significance of drug analysis of sweat in respect to rapid screening for drug abuse. Int J Leg Med 82: 251256.
  • 148
    Huestis MA, Cone EJ, Wong CJ, Umbricht A, Preston KL. 2000. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing. J Anal Toxicol 24: 509521.
  • 149
    Saito T, Wtsadik A, Scheidweiler KB, Fortner N, Takeichi S, Huestis MA. 2004. Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for Δ9-tetrahydrocannabinol in sweat patches. Clin Chem 50: 20832090.
  • 150
    Huestis MA, Scheidweiler KB, Saito T, Fortner N, Abraham T, Gustafson RA, Smith ML. 2008. Excretion of Δ9-tetrahydrocannabinol in sweat. Forensic Sci Int 174: 173177.
  • 151
    National Library of Medicine. 2009. DailyMed: Current medication information. U.S. National Library of Medicine and National Institutes of Health, Bethesda, MD.
  • 152
    RxList. 2008. The Internet Drug Index. WebMD, New York, NY, USA.
  • 153 2008. Drug Information Portal. New York, NY, USA.
  • 154
    Volmer DA, Hui JPM. 1998. Study of erythromycin A decomposition products in aqueous solution by solid-phase microextraction/liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 12: 123129.
  • 155
    Gulkowska A, He Y, So MK, Yeung LWY, Leung HW, Giesy JP, Lam PKS, Martin M, Richardson BJ. 2007. The occurrence of selected antibiotics in Hong Kong coastal waters. Mar Pollut Bull 54: 12871293.
  • 156
    Batt AL, Bruce IB, Aga DS. 2006. Evaluating the vulnerability of surface waters to antibiotic contamination from varying wastewater treatment plant discharges. Environ Pollut 142: 295302.
  • 157
    Spongberg AL, Witter JD. 2008. Pharmaceutical compounds in the wastewater process stream in Northwest Ohio. Sci Total Environ 397: 148157.
  • 158
    Christian T, Schneider RJ, Farber HA, Skutlarek D, Meyer MT, Goldbach HE. 2003. Determination of antibiotic residues in manure, soil, and surface waters. Acta Hydrochim Hydrobiol 31: 3644.
  • 159
    Thomas KV, Hilton MJ. 2004. The occurrence of selected human pharmaceutical compounds in UK estuaries. Mar Pollut Bull 49: 436444.
  • 160
    Roberts PH, Thomas KV. 2006. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Total Environ 356: 143153.
  • 161
    Trenholm RA, Vanderford BJ, Drewes JE, Snyder SA. 2008. Determination of household chemicals using gas chromatography and liquid chromatography with tandem mass spectrometry. J Chromatogr A 1190: 253262.
  • 162
    Nakada N, Kiri K, Shinohara H, Harada A, Kuroda K, Takizawa S, Takada H. 2008. Evaluation of pharmaceuticals and personal care products as water-soluble molecular markers of sewage. Environ Sci Technol 42: 63476353.
  • 163
    Nakada N, Tanishima T, Shinohara H, Kiri K, Takada H. 2006. Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment. Water Res 40: 32973303.
  • 164
    Nakada N, Shinohara H, Murata A, Kiri K, Managaki S, Sato N, Takada H. 2007. Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. Water Res 41: 43734382.
  • 165
    Reeves AD, Patton D. 2005. Faecal sterols as indicators of sewage contamination in estuarine sediments of the Tay Estuary, Scotland: An extended baseline survey. Hydrology and Earth System Sciences 9: 8194.
  • 166
    Kolpin DW, Skopec M, Meyer MT, Furlong ET, Zaugg SD. 2004. Urban contribution of pharmaceuticals and other organic wastewater contaminants to streams during differing flow conditions. Sci Total Environ 328: 119130.
  • 167
    Peng X, Yu Y, Tang C, Tan J, Huang Q, Wang Z. 2008. Occurrence of steroid estrogens, endocrine-disrupting phenols, and acid pharmaceutical residues in urban riverine water of the Pearl River Delta, South China. Sci Total Environ 397: 158166.
  • 168
    Verenitch SS, Lowe CJ, Mazumder A. 2006. Determination of acidic drugs and caffeine in municipal wastewaters and receiving waters by gas chromatography-ion trap tandem mass spectrometry. J Chromatogr A 1116: 193203.
  • 169
    Romano MJ, Dinh A. 2001. A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder. Pediatrics 108: 471472.
  • 170
    TintinalliJE, KelenGD, StapczynskiJS, MaOJ, ClineDM, eds. 2003. Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 6th ed.. McGraw-Hill, New York, NY, USA.
  • 171
    Janssen Ortho. 2008. Ortho Evra (norelgestromin/ethinyl estradiol transdermal system). 10154403. Ortho-McNeil-Janssen Pharmaceuticals, Manati, Puerto Rico.
  • 172
    Physician's Desk Reference. 2009. Medical Economics Data Production Company, Montvale, NJ, USA.
  • 173
    Friel PN, Hinchcliffe C, Wright JV. 2005. Hormone replacement with estradiol: Conventional oral doses result in excessive exposure to estrone. Altern Med Rev 10: 3641.
  • 174
    Centers for Disease Control. 2003. Nicotine poisoning after ingestion of contaminated ground beef—Michigan, 2003. MMWR Morb Mortal Wkly Rep 52: 413416.
  • 175
    Key Pharmaceuticals. 2004. NITRO-DUR (nitroglycerin)—Transdermal infusion system: Product information. Kenilworth, NJ, USA.
  • 176
    Balit CR, Lynch A-M, Gilmore SP, Murray L, Isbister GK. 2006. Lignocaine and chlorhexidine toxicity in children resulting from mouth paint ingestion: A bottling problem. J Paediatr Child Health 42: 350353.
  • 177
    Sanofi-Aventis. 2006. Prescribing information—Demerol (meperidine HCL) 50 mg tablets. 104774. Bridgewater, NJ, USA.